Clinical Trial Update: Pharmacokinetic, Efficacy and Safety of BT524 in Patients With Congenital Fibrinogen Deficiency [Phase 3]

View source ↗

Summary

Phase 3 study evaluating pharmacokinetics, efficacy, and safety of BT524 in patients with congenital fibrinogen deficiencies (afibrinogenemia and hypofibrinogen…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Congenital Afibrinogenemia
• Congenital Hypofibrinogenemia

Drugs mentioned

• BT524

Snippet

Sponsor: Biotest | Conditions: Congenital Afibrinogenemia, Congenital Hypofibrinogenemia | Phase 3 | Status: COMPLETED | Results posted: 2025-07-03